We have moved to new location, Please click on contact us  
Home  >  News
you can get e-magazine links on WhatsApp. Click here
Policy & Regulations + Font Resize -

NPPA fixes retail price of 84 formulations

Our Bureau, New Delhi
Tuesday, July 5, 2022, 09:00 Hrs  [IST]

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 84 formulations including pain relief drugs, anti-diabetes drugs, cholesterol lowering drugs among others from various companies. The decision was taken in a recently held Authority meeting.

The formulations for which retail prices were fixed include voglibose (sustained release) and metformin hydrochloride tablet (Rs 10.47per tablet); and olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet marketed by German Remedies (Rs. 12.91 per tablet); hydroxychloroquine sulphate tablet from Hetero Healthcare (Rs. 11.74 per tablet); linezolid for oral suspension (combipak with steril water) marketed by Eris Healthcare Pvt Ltd (Rs. 102 per combi pack); paracetamol and caffeine tablets by Dabur India; and paracetamol and ibuprofen suspension marketed by Dales Laboratories (Rs. 0.33 per one ML).

Metformin hydrochloride sustained release, glimepiride and voglibose combination tablets marketed by Sun Pharmaceuticals with various strengths also witnessed retail price fixation. Prices for various strengths of rosuvastatin, aspirin and clopidogrel capsules; glimepiride, pioglitazone hydrochloride and metformin hydrochloride tablets marketed by German Remedies Pharmaceuticals; amoxycillin and potassium clavulanate tablets of various strengths marketed by Themis Medicare Ltd; ceftriaxone and tazobactam for injection marketed by Cadila Pharmaceuticals (Rs. 168.43 per vial) are some of the other products for which prices were fixed by the Authority.

Various strengths of diabetes drug sitagliptin phosphate and metformin hydrochloride combinations, marketed by companies including Alembic Pharma, Abbott Healthcare Ltd, Torrent Pharmaceuticals, Skymap Pharmaceuticals among others also sees retail price fixed through the meeting held by the NPPA in the end of June, 2022. It may be noted that the patent for sitagliptin is in the verge of reaching its expiry and despite the concerns raised by the research-based large multinationals, NPPA has earlier decided to go ahead with fixing the retail price.

Similarly, prices of dapagliflozin combinations, which was also a patented drug of AstraZeneca in the recent past, were also fixed during the meeting.

The prices fixed are excluding Goods and Services Tax (GST) and manufacturers may add GST only if they have paid actually or it is payable to the Government on the retail price mentioned by the NPPA, it added.

The retail price for a pack of the formulations listed shall be arrived at by the concerned manufacturer in accordance with the retail price specified by the NPPA as per provisions contained in Paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form V from date of Notification as per paragraph 24 of the DPCO 2013, to NPPA and submit a copy to the State Drug Controller and dealers.

Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.


* Name :     
* Email :    
  Website :  
India Lab Expo
Copyright © 2016 Saffron Media Pvt. Ltd |